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Our objective was to compare therapeutic outcome and analyse cost-benefit of a ‘conventional’ (7-day course of i.v. 
antibiotic therapy) vs. an abbreviated (2-day i.v. antibiotic course followed by ‘switch’ to oral antibiotics) therapy for 
in-patients with community-acquired pneumonia (CAP). We used a multicenter prospective, randomized, parallel 
group with a 28 day follow-up, at the University-based teaching hospitals: The Medical Center of Louisiana in 
New Orleans, LA and hospitals listed in the acknowledgement. 
Ninety-five patients were randomized to receive either a ‘conventional’ course of intravenous antibiotic therapy 
with cefamandole 1 g i.v. every 6 h for 7 days (n=37), or an abbreviated course of intravenous therapy with 
cefamandole (1 g i.v. every 6 h for 2 days) followed by oral therapy with cefaclor (500 mg every 8 h for 5 days). No 
difference was found in the clinical courses, cure rates, survival or the resolution of the chest radiograph 
abnormalities among the two groups. The mean duration of therapy (6.88 days for the conventional group compared 
to 7.30 days for the early oral therapy group) and the frequencies of overall symptomatic improvement (97% vs. 95%, 
respectively) were similar in both groups. Patients who received early oral therapy had shorter hospital stays (7.3 vs. 
9.71 days, P=O.Ol), and a lower total cost of care ($2953 vs. $5002, PcO.05). 
It was concluded that early transition to an oral antibiotic after an abbreviated course of intravenous therapy in 
CAP is substantially less expensive and has comparable efficacy to conventional intravenous therapy. Altering 
physicians’ customary management of hospitalized patients with CAP can reduce costs with no appreciable 
additional risk of adverse patient outcome. 
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Introduction 
It is generally agreed that patients with severe community- 
acquired pneumonia or community acquired pneumonia 
and significant co-morbidity should be hospitalized 
and receive parenteral antibiotics (1,2). This therapeutic 
strategy, utilized in up to 20% of pneumonia cases, results 
in one million hospital admissions per year with an average 
length of stay of 6.3 days (3). Patients 65 years of age and 
older usually remain hospitalized for much longer (4). Since 
accurate and timely identification of the causative organism 
is often difficult, empirical selection of a broad-spectrum 
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antimicrobial agent active against the most commonly 
encountered pathogens is usually necessary (5,6). A number 
of studies have suggested that in older patients (especially 
those residing in nursing homes), alcoholics and individuals 
with chronic obstructive lung disease, a second-generation 
cephalosporin represents a reasonable initial empiric anti- 
biotic choice (5-13). Recent research efforts have focused 
on early ‘switch’ to oral antibiotics after an initial clinical 
response to empiric treatment has occurred. The duration 
of drug administration in the hospital and at home has 
often been determined arbitrarily on the basis of custom 
and personal prejudice (1). Siegel et al. have recently 
suggested that ‘adult patients who are not severely ill can be 
successfully treated with an abbreviated (2-day) course of 
intravenous antibiotics and then switched to oral therapy. 
A longer course of intravenous therapy prolongs hospital 
stay and cost, without improving the therapeutic cure 
rates (14). In a retrospective study, Weingarten et al. had 
identified that at least 33”/0 of hospitalized patients with 
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pneumonia were ‘low risk’ and could be switched to an oral 
regimen and discharged on the 3rd hospital day (15). To 
date, however, there have been only a few prospective 
studies which have investigated the optimum number of 
days of intravenous antibiotic treatment for community- 
acquired pneumonia and its effect on hospital discharge, 
patient outcomes, and the cost of their care. 
To determine if patients requiring hospitalization for 
community- acquired pneumonia could be switched to oral 
therapy after an abbreviated intravenous antibiotic course, 
we performed a multicenter prospective randomized study 
and compared patients’ clinical course, outcomes, and cost 
of care. 
Materials and Methods 
POPULATION STUDY AND THERAPY 
Pneumonia was defined as per the American Thoracic 
Society (ATS) guidelines based on clinical findings and a 
new infiltrate on the chest radiography. Additionally, 
diligent effort was made to attribute bacteriology, if at all 
possible. A sample size of 32-34 patients in each group was 
necessary to detect a 15-20% difference between the two 
groups. Patients over 18 years of age were entered in the 
study after written informed consent was obtained. The 
decision for admission to the hospital was made by admit- 
ting residents or attending staff physicians based on their 
clinical judgment, independent of study investigators. These 
patients would be considered moderate to severely ill and 
all had met the criteria for hospitalization for the treatment 
of clinically suspected community-acquired bacterial pneu- 
monia. Most of these patients had co-morbid illnesses, 
and/or hypoxemia, and/or immunosuppressive disorders; 
and most had vital signs abnormal enough to require 
admission. Patients were considered to have bacterial pneu- 
monia if they had a temperature exceeding 38°C a new 
pulmonary infiltrate determined by chest radiograph, and a 
cough productive of purulent sputum (predominance of 
neutrophils on Gram stain). Patients were excluded if they 
were pregnant or moribund, known to have an allergy to 
cephalosporins or penicillins, or had other apparent con- 
comitant infections. Patients were also excluded if they had 
received antibiotic treatment within 3 days prior to entry, 
had an organism known to be resistant to the study drug(s), 
had significant underlying diseases that could interfere with 
the ability to evaluate response, had an infection at a site 
where neither study drug had an approved indication, or 
were recently (~30 days) discharged from the hospital. 
A complete medical history and physical examination 
were obtained prior to entry into the study. All patients 
were treated initially with cefamandole nafate (Mandol It, 
Lilly) 1 g i.v. every 6 h for a minimum of 48 h. After this 
initial period of parenteral therapy, each eligible patient 
was assigned by a computer-generated sequence of random 
numbers to receive one of two treatment regimens for at 
least 5 more days: (1) continued parenteral cefamandole 1 g 
every 6 h, or (2) change to oral cefaclor (Ceclor’@, Lilly) 
500 mg every 8 h. These drugs were acceptable standard 
antibiotics for pneumonia during the study period. Even 
though there are many antibiotics that require less frequent 
administration, recent studies indicate that older antibiotics 
that have fallen out of favor, are still effective for the 
treatment of community-acquired pneumonia. Despite the 
frequency of administration, the generic formulation of 
these antibiotics may even be more economical (16). If the 
primary physician decided a particular patient’s condition 
did not permit randomization, that patient continued to 
receive cefamandole for an additional 48 h and randomiza- 
tion was delayed. Most of the time this decision was based 
on the primary physicians’ subjective assessment of the 
patient’s response to therapy. We had to permit this since at 
that time abbreviated intravenous antibiotic therapy was a 
novel approach. After that 48-h period, the patient was 
randomized to one of the treatment regimens for at least 
3 days (minimum of 5 total days of antibiotic treatment), 
if feasible. 
Physical examinations were repeated as necessary during 
hospitalization to assess the clinical course of each patient 
and to monitor for adverse drug events. All patients were 
scheduled to have at least one follow-up visit 24 weeks 
after hospital discharge. 
LABORATORY INVESTIGATIONS 
Before the start of antibiotic therapy, specimens for culture 
were collected from one or more of the following sources: 
expectorated sputum, nasotracheal aspirate, transtracheal 
aspirate, bronchoscopic aspirate, or pleural fluid aspirate. 
A repeat culture from one of the above sources was 
obtained prior to discontinuation of cefamandole and if 
possible , again after completion of either regimen. A 
minimum of two blood cultures were drawn on each patient 
prior to beginning antibiotic therapy. 
A chest radiograph was taken before therapy and prior to 
discontinuation of cefamandole. If the pulmonary infiltrate 
had not resolved by the time of discharge from the hospital, 
a chest radiograph was taken at the follow-up office visit to 
assess resolution of the infiltrates. 
Before initiation of therapy, a CBC and differential, 
platelet count, prothrombin time, urinalysis (including 
microscopic examination), BUN, serum creatinine, SGOT 
and/ or SGPT, bilirubin, and alkaline phosphatase were 
measured. Any laboratory tests thought to be clinically 
indicated were repeated at the discretion of the primary 
physician. 
EVALUATION OF RESPONSE 
Satisfactory response was defined as the resolution of fever 
(~38°C or 100.4”F) for a period of at least 48 h, improve- 
ment of the patient’s respiratory signs and symptoms, and 
stability or improvement of the chest radiographic findings. 
At that time, 48 h. was considered the minimum acceptable 
period without fever before switching to oral therapy and 
was imposed by the IRB. Unsatisfactory response was 
defined as either the failure to achieve a satisfactory 
response on the study drug as defined above, or recurrence 
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of pneumonia (due to the original pathogen) within 1 week 
following discontinuation of the study drug. 
The pathogen was considered to be eliminated if the 
pathogen isolated before therapy was no longer present in 
the culture obtained after discontinuation of therapy. 
Superinfection was defined as the presence of purulent 
sputum with a new pathogen seen on the Gram-stain 
or culture, accompanied by deterioration in the patient’s 
clinical or radiographic status. The pathogen was consid- 
ered to persist if the therapy failed to eradicate the original 
pathogen as indicated by the culture results obtained after 
discontinuation of study drug. The bacteriological response 
was not evaluated if; (1) the patient was entered in violation 
of the entry criteria, (2) the patient required another 
antibiotic during evaluation of the study drug (for a non- 
pneumonic diagnosis), (3) the patient received less than 3 
days of study drug therapy, or (4) a repeat sputum or 
acceptable aspirate culture at the end of study drug therapy 
was not obtained. 
HOSPITAL STAY 
Patients were discharged as their clinical conditions 
permitted or after intravenous therapy was completed in 
the intravenous cefamandole group (5-7 days, whichever 
was later). Hospital discharge in both groups was at the 
discretion of the primary physician, and based upon an 
overall appraisal of the patient’s clinical status. 
HOSPITALIZATION COSTS 
The total inpatient bill and an estimation of outpatient 
costs were recorded and compared between groups. This 
included daily hospital charges, laboratory fees, and phar- 
macy administration and drug costs based on patients’ 
hospital bills. Outpatient costs were estimated for a 
follow-up phone call, a clinic visit to a nurse practitioner, 
and sputum costs if and where applicable, based on the 
customary charges. 
RESULTS 
Between October 1985 and October 1987, 135 patients were 
initially enrolled in the study. Forty patients, the majority 
in the conventional therapy group, had to be dropped from 
the study, primarily because of protocol violations (n = 25); 
or because the diagnosis of pneumonia could not be proven 
by radiographic, clinical, or bacteriological evidence 
(n = 15). Protocol violations consisted mostly of medication 
errors and concomitant use of other antibiotics. Thirty- 
seven patients in the conventional therapy group and 58 in 
the early oral therapy group completed the study protocol. 
The wide discrepancy in the number of patients in the two 
groups was the result of increased protocol violations in the 
conventional group (more medication errors and more 
concomitant antibiotics use, etc). One explanation may be 
that these patients were on intravenous antibiotics for 
longer period of times during which time more errors were 
likely to occur. Thirty-four of 37 in the conventional 
therapy and 40 out of 58 in the early oral therapy group, 
were randomized after 48 hours of intravenous antibiotic 
therapy. The remaining patients were randomized after 96 h 
at primary physicians’ discretion. 
DEMOGRAPHIC CHARACTERISTICS 
The mean age was 63.5 years (range, 17-93 years) in the 
conventional therapy group and 60.5 years (range, 18-95 
years) in the early oral therapy group. The treatment 
groups were similar in regards to age and underlying 
illnesses. There were no differences in age, sex (60% male, 
40% female), or race (44% black, 32% Hispanic, 24% 
white). These patients would be considered moderate to 
severely ill and all had met the criteria for hospitalization 
for the treatment of clinically suspected community- 
acquired bacterial pneumonia. Most of these patients had 
co-morbid illnesses, and/or hypoxemia, and/or immuno- 
suppressive disorders; and most had vital signs abnormal 
enough to require admission. The majority of admitted 
patients had chest pain, persistent nausea and vomiting, 
dehydration, multilobar infiltrates, and/ or major 
co-morbidity. 
PATIENT OUTCOMES 
The overall rate of clinical response was similar for the two 
treatment groups (97% conventional therapy group vs 95% 
early oral therapy). Two deaths in the conventional therapy 
group and three deaths in the cefaclor group were reported. 
All of the deaths occurred several days after discontinuing 
the study drugs and were related to complications of the 
patients’ underlying diseases. The clinical responses of 
patients are summarized in Table 1. 
MICROBIOLOGY DATA 
Infecting organisms were identified in 72 (76%) of patients: 
42 (72%) of the early oral therapy group and 31 (84%) of 
the conventional therapy group (Table 2). As expected, 
Streptococcus pneumoniae was the single most common 
organism isolated. One patient in each treatment group 
failed therapy. In the conventinal therapy group, the iso- 
lated pathogen from the failure patient was Serratia species; 
in the early oral therapy group, multiple pathogens had 
been isolated from the pre-therapy sputum culture of the 
failure patient. Two patients who initially responded to 
early oral therapy subsequently relapsed, while none of the 
responders relapsed after conventional therapy. Of the two 
relapses in the early oral therapy group, one had had 
Klebsiella pneumoniae and the other had both S. pneumo- 
niae and Staphylococcus aureus isolated from the pre- 
therapy sputum culture. All three of these isolates were 
sensitive to both cefaclor and cefamandole. 
Eleven patients (11.6%) had S. pneumoniae isolated from 
pre-therapy blood cultures. Six (1%) of these patients were 
in the early oral therapy group (n = 58), and five (1.3%) were 
in the conventional therapy group (n=37). All of these 
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FIG. 1. This graph plots the difference between the length 
of hospital stay for the cefamandole (- -W- -) and the 
cefamandolekefaclor (-) (early oral therapy) group; the 
number of days a patient spent in the hospital and the 
frequency of discharge. A much higher percentage of 
patients in the cefamandolekefaclor (early oral therapy) 
group were discharged during the first 5 days (43% W. 
11%). In contrast, the majority of patients in the cefa- 
mandole (conventional therapy) group were discharged 
between Day 7 and Day 10. 
patients were clinically cured. One patient in the early oral 
therapy group grew Haemophilus species, and this patient 
also achieved a clinical cure. Efforts to correlate bacterio- 
logical eradication by the therapy were unsuccessful 
because of the inability to obtain follow-up sputum culture 
specimens in most patients. Patients with positive blood 
cultures in both groups had the same outcome and response 
to therapy. There were not enough patients with positive 
blood cultures in each group to evaluate for length of stay. 
Blood cultures are not cost-effective in the evaluation of 
community-acquired pneumonia (17,18). 
RADIOLOGY 
All patients had a new infiltrate as required by the inclusion 
criteria. All infiltrates had resolved or were resolving by the 
time of the outpatient follow-up visit. 
COST ANALYSIS 
In this study, 95 patients were randomized to receive either 
daily intravenous antibiotics for at least 5 days or an 
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abbreviated course of intravenous therapy followed by oral 
therapy. The majority of patients, 91.9% of the conven- 
tional therapy group and 68.9% of the early oral therapy 
group, were randomized at 48 h. Only three patients (11%) 
in the conventional therapy group, received the minimum 5 
days of parenteral therapy and left the hospital. The 
majority of the rest received 7 days of intravenous therapy, 
but remained in the hospital 2 additional days after com- 
pletion of antibiotics; presumably for observation; their 
additional cost averaged $2013.62. 
The relationships of the antibiotic regimen to the 
duration and costs of treatments are outlined in Table 3. 
The mean number of days on therapy was similar for the 
intravenous (6.88 days) and the early oral group (7.30 
days). The number of days in the hospital was significantly 
longer for patients receiving intravenous cefamandole 
(9.7 f 0.9 days vs. 7.3 & 0.8 days; WO.01). Figure 1 shows 
the percentage of patients discharged from the hospital each 
day after enrollment. The early oral therapy group had a 
higher percentage of patients leaving the hospital early after 
randomization. The conventional therapy group required a 
minimum of 5 hospital days. The few patients in each group 
who remained hospitalized after 10 days (25% of the 
conventional therapy group and 13% of the early oral 
therapy group) were similar in respect to complications 
(e.g. cerebrovascular accident, pulmonary infarction, 
myocardial infarction). 
The total inpatient charges were considerably higher for 
the conventional therapy group (Table 3). The average 
hospital cost was $540 daily (range $2888$746 depending 
on the hospital). Elements of cost in addition to the hospital 
rate included expenditures for chest and other radiographs, 
laboratory tests, electrocardiograms, and pharmacy costs. 
Administration, and drug costs for intravenous cefaman- 
dole averaged $240 per day, compared with $2 per dose for 
cefaclor. Additional expenses beyond hospital days and 
pharmacy costs in the cefamandole group were incurred for 
non-protocol laboratory and radiographic tests performed 
at the discretion of the managing physicians. Outpatient 
costs for each group were small and were not significantly 
different (Table 3). 
ADVERSE EFFECTS 
Adverse events occurred in nine (24.3%) of the conventional 
therapy group and 11 (18.9%) of the early oral therapy 
group patients (Table 3). The most common side effect was 
gastrointestinal distress, which occurred in four of the 
conventional therapy group and two of the early oral 
TABLE 1. Relationship of clinical response to therapy 
Clinical response (number of patients) 
Therapy Improvement Failure Relapse Death 
Standard intravenous (cefamandole) 36 (97.3%) 1 0 2 (5.4%) 
Early oral treatment (cefaclor) 55 (94.8%) 1 2 3 (5.1%) 
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TABLE 2. Bacteriology data 
Cefaclor Cefamandole 
Total number Total number 
(failed*/relapsedt) (failed*) 
Streptococcus pneumoniae 
Streptococcus viridans 
Streptococcus, Group H 
Streptococcus species 
Hemophilus infuenzae 
Hemophilus species 
Klebsiella pneumoniae 
Klebsiella oxytoca 
Enterobacter cloaecae 
Serratia species 
Multiple organisms, including anaerobes 
No organism identified 
Normal flora 
Total 
12 
1 
1 
2 
4 
1 
1 (ItI 
1 
1 
1 (I*) 
17 (It> 
15 
1 
58 (l*, 2-t) 
13 
0 
0 
3 
2 
2 
0 
0 
0 
0 
11 (l*) 
3 
37 (l*) 
*Failed clinical response. 
tRelapsed after initial response. 
TABLE 3. Mean duration of therapy, duration of hospitalization, charges, and adverse events 
Cefamandole Cefaclor P 
Days on therapy 
Days in hospital 
Charges 
Average in hospital costs 
Average follow-up costs 
Total costs 
Death 
General 
Cardiovascular system 
Digestive system 
Nervous system 
Respiratory system 
Urogenital system 
Total adverse events 
6.88 7.30 
9.7 ( f 0.9) 7.3 ( zk 0.8) 
n=37 n=58 
$4894.70 
$106.87 
$5001.57 
3 
2 
3 
4 
2 
0 
0 
14 
$2883.07 
$69.4 1 
$2952.48 
2 
1 
3 
2 
1 
1 
1 
11 
n.s. 
co.01 
<o.os 
ns. 
co.05 
ns. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
therapy group patients. Other adverse events were minor, 
were similar to those noted in other studies of patients with 
pneumonia (lo), and led to a discontinuation of the drug in 
only two individuals: one of the conventional therapy 
group with a maculopapular rash and one the early oral 
therapy group with diarrhea. 
Discussion 
In comparison to previous studies investigating duration of 
in-hospital antibiotic therapy for patients with community- 
acquired pneumonia, the current study has distinctive 
advantages. Most of the previous studies have been limited 
by retrospective design, restriction to a narrow population 
(i.e. veterans), or small size of study population, or pro- 
longed intravenous therapy prior to switch (5 days). Our 
study was prospective and we did not enroll any patient 
without clear cut evidence of pneumonia. Furthermore, the 
majority of previous studies used a ‘clinical’ diagnosis of 
pneumonia as is customary in general practice. The lack of 
bacterial criteria in these studies further increases concern 
over the small sample size in these reports. The reason for 
the high percent of etiological pathogen found in the 
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present investigation, is two-fold. To begin with, we made a 
concerted effort to attribute bacterial etiology to distinguish 
this study from the previous ones where the diagnosis of 
pneumonia was suspect (Table 2). Furthermore, some of 
the patients with unidentified organisms were dropped 
because of other violations, such as the use of other 
antibiotics. 
Early switch to oral therapy has recently gained wider 
acceptance. Gentry et al. have shown that parenteral fol- 
lowed by oral ofloxacin therapy for nosocomial and 
community-acquired pneumonia was safe, but the average 
length of intravenous therapy in that study was 5.7 days 
(19). Continued intravenous therapy for 7-14 days is rec- 
ommended frequently, with modifications in this strategy 
based upon factors applying to each individual (1). Ramirez 
et al. have reported that an early switch to oral cefixime 
may be reasonable in hospitalized patients with 
community-acquired pneumonia who have already shown a 
good response to therapy with intravenous third-generation 
cephalosporin (20). 
In the current study, the early oral therapy group had 
a higher percentage of patients leaving the hospital after 
randomization occurred. There were no fixed clinical 
criteria for discharge. Decision to discharge as commonly 
occurs in clinical practice was based on the primary physi- 
cian’s judgment. The conventional therapy group required 
a minimum of 5 hospital days. A review of medical records 
failed to demonstrate objective reasons for prolonged stay 
beyond 7 days for the conventional therapy group respond- 
ers. Three conventional therapy group (11%) and 18 early 
oral therapy group (31.1%) patients randomized at 96 h 
may have contributed to their longer hospitalizations. The 
small difference in hospital stay in the two groups was the 
result of the reluctance by the primary care physicians to 
discharge. It should also be pointed out that 18 out of 58 of 
the cefaclor group (31.1%) and only four out of 37 of the 
control group (11%) had delayed randomization. This may 
indicate that the early oral therapy group may have been 
more severely ill. However, the outcome was the same 
between the two groups. 
As shown in Fig. 1, it is clear that a much higher 
percentage of patients in the early oral therapy group (43%) 
left the hospital during the first week. The satisfactory 
outcome of this group of patients discharged early on oral 
antibiotics demonstrates that it is safe for a majority of 
hospitalized patients with community-acquired pneumonia 
to leave the hospital in less than 5 days following an initial 
intravenous antibiotic response. 
The choice of antibiotics, however, remains contro- 
versial. As documented in previous studies, a second- 
generation cephalosporin was very successful in the 
treatment of severe community-acquired pneumonia 
(4,5,13), resulting in clinical resolution of illness in 957% of 
these patients. The optimum duration and mode of anti- 
biotic therapy for hospitalized patients for community- 
acquired pneumonia and the data regarding the role of 
particular microbiology isolates upon this decision are 
unknown (21-23). Contrary to classic teaching, but consist- 
ent with observations in clinical practice, identification of 
the specific bacterial etiology of pneumonia was not essen- 
tial to a satisfactory therapeutic response in most patients. 
This observation is consistent with the British observation 
and the ATS guidelines that the timing of initial empiric 
antibiotic treatment is more important in determining out- 
come than the precise agent chosen by physicians and the 
role of sputum smear and culture currently remains contro- 
versial (2,14). Fine et al. have recently demonstrated that 
the there is no evidence that the newer, more expensive 
antibiotics have improved outcome in the treatment of 
CAP. Indeed, the authors concluded the use of erythro- 
mycin as recommended by the ATS guidelines is still as 
effective as ever for treatment community-acquired 
pneumonia (24). In 1987, cefamandole was the accepted 
most commonly used antibiotic for the treatment of 
community-acquired pneumonia, just as cefuroxime is now. 
Even though a variety of organisms were isolated during 
the course of the study, efforts to correlate bacteriological 
eradication by the therapy were unsuccessful because of the 
inability to obtain follow-up sputum culture specimens in 
most patients. This problem typically relates to the rapid 
resolution of cough and sputum production during anti- 
microbial therapy. This finding is by no means atypical and 
most authorities base the initial treatment of CAP on the 
suspected etiologic agent(s) (2,25). When the clinical setting 
and results of preliminary diagnostic tests do not identify 
an obvious pathogen, broad-spectrum antibiotics are often 
continued (2,&6), with the appropriateness of this treat- 
ment decision determined by the therapeutic response (2). 
Although in our study bacteriological response could not be 
documented as such, the uniformly good response suggests 
a high efficacy for both regimens. 
Both treatment groups included some patients who 
required prolonged hospitalization due to concomitant 
medical problems selected by criteria prompting initial 
admission (e.g. severe cardiac, renal or chronic pulmonary 
disease) or by subsequent complications (e.g. acute myo- 
cardial infarction, stroke, pulmonary embolism, etc). In 
spite of the abbreviated intravenous therapy in the early 
oral therapy group, 13% of these patients (vs. 25% in 
conventional therapy group) required more than 10 days of 
hospital stay and contributed to the mean length of stay 
(Table 3). A similar number of patients in both groups had 
minor complications from the primary infection which 
slightly postponed hospital discharge. All of the deaths 
occurred several days after discontinuing the study drugs 
and occurred in the highest risk patients. These deaths were 
secondary to the patients’ underlying disease, and probably 
not related to the diagnosis of pneumonia. 
In the current managed care milieu, several opposing 
forces influence utilization of resources. On the one hand, 
physicians are trained to attempt to minimize uncertainty 
and this may lead to overutilization of resources. On the 
other hand, managed care economic influences forces 
physicians to practice with increasing levels of uncertainty 
in order to minimize utilization of resources (26). The 
incentive to conserve resources may become so strong so as 
to induce underutilization of resources and may result in an 
unacceptable quality of care. A ‘delicate balance’ has to be 
struck between these two forces if acceptable care is to be 
delivered while optimizing utilization of resources (26). In 
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an attempt to alleviate physicians’ uncertainty, a few studies 
have addressed this issue, but have been limited by retro- 
spective design, restriction to a narrow population (i.e. 
veterans), or small size of study population. Furthermore, 
all of these studies used a ‘clinical’ diagnosis of pneumonia 
as is customary in general practice. The lack of bacterial 
criteria in these studies further increases concern over the 
small sample size in these reports. In the present investiga- 
tion, we made a concerted effort to attribute bacterial 
etiology. 
The treatment cost of each regimen in this study was 
substantially different. Early discharge of pneumonia 
patients clinically improving on oral therapy, appears safe 
and cost-effective. Based on this study, the reduced costs 
of this ‘switch therapy’ strategy could realize substantial 
savings annually. Outpatient charges for each group were 
small and similar. 
The multicenter nature of this study suggests that the 
results are exportable to most hospitals. Physician customs 
and clinical prejudice contribute heavily to the length of 
hospital stay, mode of therapy, and ultimate costs of 
patient care. Uncertainty about the values and limitations 
of treatment options can be reduced, but not abolished, 
through large randomized clinical trials (26). However, the 
inherit conflict between managed care and physician that is 
based on this uncertainty, can be ameliorated. With the 
current availability of increasingly effective oral antimicro- 
bials, better definition of the impact of such factors is 
clearly needed. 
Acknowledgements 
The authors would like to thank Eli Lilly Research 
Laboratories and the following investigators who con- 
tributed patient data to this study: T. P. Greco, MD; 133 
Scoville Street, Waterbury, CT: C. Bainbridge, MD; 
Pulmonary Associates, 303 West 24th Street, Sioux City, 
IA: K. Jacobson; 1180 Paterson, Ste. 2-A, Eugene, OR: 
Richard N. Greenberg; St. Louis University College of 
Medicine, Division of Infectious Diseases, 1402 South 
Grand Boulevard, St. Louis, MO: Drs. DeLormel 
Clermont; Chief Department de Microbiology, Hospital 
Charles LeMoyne, 212 Blvd. Taschereau, Greenfield Park, 
Quebec: J. Southard, MD, Ph.D., 4718 Engle Road, 
Suite K, Carmichael, CA. 
References 
1. Johnson CC, Finegold SM. Pyogenic bacterial 
pneumonia, lung abscess, and empyema. Respir Med 
1988; 1: 803-855. 
2. Neiderman MS, Bass BJ, Campbell GD et al. Guide- 
lines for the initial management of adults with 
community-acquired pneumonia: diagnosis, assessment 
of severity, and initial antimicrobial therapy. Am Rev 
Respir Dis 1993; 148: 1418-1426. 
3. Data from National Health Survey, Detailed diag- 
noses and procedures. National Hospital Discharge 
Survey. Vital and health statistics. Series 13. 1992; 113: 
1-225. 
4. Summer WR, Nelson S. Severe community-acquired 
pneumonia. How to decide on initial therapy. Pulmon 
Perspect 1988; 5: 4-8. 
5. Pennington JE. Community-acquired pneumonia and 
acute bronchitis. In Respiratory Infection Raven Press, 
1983: 125-134. 
6. Donowitz GR, Mandell GF. Introduction: community- 
acquired pneumonias where are we now? Semin Respir 
Znfect 1989; 4: 1-3. 
7. Geckler RW, McAllister K, Gremillion DH, 
Ellenbogen C. Clinical value of paired sputum and 
transtracheal aspirates in the initial management of 
pneumonia. Chest 1985; 87: 631-635. 
8. Sanders CV, Greenberg RN, Marier RL. Cefamandole 
and cefoxitin. Arm Intern Med 1985; 103: 70-78. 
9. Garb JL, Brown RB, Garb Jr et al. Differences in 
etiology of pneumonias in nursing home and commu- 
nity patients. J Am Med Assoc 1978 240: 2169-2172. 
10. Schleupner CJ, Anthony WC, Tan J et al. Blinded 
comparison of cefuroxime to cefaclor for lower respir- 
atory tract infections. Arch Intern Med 1988; 148: 
343-348. 
1. Cockerill FR III, Edson RS. Trimethoprim- 
sulfamethoxazole. Mayo Clin Proc 1983; 58:147-153. 
2. Thompson RL, Wright AJ. Cephalosporin antibiotics. 
Mayo Clinproc 1983; 58: 79-87. 
3. Donowitz GR, Mandell GF. Beta-lactam antibiotics. 
N Engl J Med 1988; 318: 419426. 
14. The British Thoracic Society and Public Health 
Laboratory Service. Community-acquired pneumonia 
in adults in British hospitals in 1982-1983: A survey of 
aetiology, mortality, prognostic factors and outcome. 
Q J Med 1987; 239: 195-220. 
15. Weingarten SR, Riedinger MS, Varis G et al. Identifi- 
cation of low-risk hospitalized patients with pneumonia 
for early conversion to oral antimicrobial therapy. 
Chest 1994; 105: 1109-1115. 
16. Gleason PP, Kapoor WN, Stone RA et al. Medical 
outcomes and antimicrobial costs with the use of the 
American Thoracic Society guidelines for outpatients 
with community-acquired pneumonia. J Am Med Assoc 
1997; 278: 32-9. 
17. Chalasani NP, Valdecanas MA, Gopal AK, McGowan 
JE Jr, Juardo RL. Clinical utility of blood cultures in 
adult patients with community-acquired pneumonia 
without defined underlying risks. Chest 1995; 108: 
932-936. 
18. Woodhead MA, Arrowsmith J, Chamberlin-Webber R, 
Wooding S, Williams I. The value of routine micro- 
biological investigation in community-acquired pneu- 
monia. Respir Med 1991; 85: 313-317. 
19. Gentry LO, Rodriguez-Gomez G, Kohler RB, Khan 
FA, Rytel MW. Parenteral followed by oral ofloxacin 
for nosocomial pneumonia and community-acquired 
pneumonia requiring hospitalization. Am Rev Respir 
Dis 1992; 145: 31-35. 
20. Ramirez JA, Srinath L, Ahkee S, Huang, Raff MJ. 
Early switch from intravenous to oral cepahlosporin in 
ORALANTIBIOTICTHERAPYFOR CAP 1039 
the treatment of hospitalized patients with community- 
acquired pneumonia. Arch Intern Med 1995; 155: 
1273-1276. 
21. Kunin CM. Cost-effective use of antibiotics. Arch 
Intern Med 1988; 148: 1709-1710. 
22. Poretz DM, Woolard D, Eron LJ et al. Outpatient use 
of ceftriaxone: a cost-benefit analysis. Am J Med 1984; 
77: 77-83. 
23. Avorn J, Soumerai SB, Taylor W et al. Reduction 
of incorrect antibiotic dosing through a structured 
educational order form. Arch Intern Med 1988; 148: 
1720-1724. 
24. Fine MJ, Auble TE, Yealy DM et al. A prediction rule 
to identify low-risk patients with community-acquired 
pneumonia. N Engl J Med 1997; 336: 243-250. 
25. Tobin MJ. Diagnosis of pneumonia: techniques and 
problems. Clin Chest Med 1987; 8: 513-527. 
26. Mirvis DM, Chang CF. Managed care, managing 
uncertainty. Arch Intern Med 157: 385-388. 
